AstraZeneca has submitted an sNDA to the FDA for a new indication for Seroquel for the treatment of patients with depressive episodes associated with bipolar disorder. Seroquel is currently approved for the treatment of acute manic episodes associated with bipolar I disorder and the treatment of schizophrenia. The sNDA submission is based on results from the BOLDER I and BOLDER II (BipOLar DEpRession) trial programs. Both studies were double-blind, placebo-controlled trials of outpatients w...